Titre du document / Document title

(+)-Z-bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats

Auteur(s) / Author(s)

BANZ William J. ; DAVIS Jeremy ; STEINLE Jena J. ; ADLER Stuart ; OITKER Jennifer ; WINTERS Todd A. ; HIGGINBOTHAM D. Allan ; YUQING HOU ; HENRY Nancy ; PETERSON Richard ; MEYERS Cal Y. ;

Résumé / Abstract

Objective: The putative selective estrogen receptor modulator (+)-Z-bisdehydrodoisynolic acid (Z-BDDA) has been found to improve cardiovascular risk in rodents. The objective of this study was to investigate the effectiveness of (+)-Z-BDDA compared with the antidiabetic drug, rosiglitazone, in treating obesity and risk factors associated with the metabolic syndrome. Research Methods and Procedures: Female Zucker Diabetic Fatty rats were randomly assigned to three treatment groups for 29 weeks: control (C), 1.8 mg (+)-Z-BDDA/kg diet [control diet + (+)-Z-BDDA (CB)], or 100 mg rosiglitazone/kg diet [control diet + rosiglitazone (CR)]. At sacrifice, physiological, biochemical, and molecular parameters were examined. Results: CB animals gained less weight and exhibited a decrease in total body lipids (p < 0.05) as compared with C or CR rats. Body weight and total body lipids were the highest in CR rats (p < 0.05). Liver weights in CB and CR rats were lower (p < 0.05) than in C rats, whereas kidney weights were lower in CB (p < 0.05) than in C and CR animals. Fasting plasma glucose was lower (p < 0.05) in the CB and CR animals when compared with C animals. C rats exhibited the highest concentration of total plasma cholesterol, and CR-treated rats exhibited the lowest concentration. Plasma triglycerides followed the same pattern as plasma cholesterol. Histomorphometry of heart vasculature revealed that CB and CR treatments produced a significant shift from small to large venules and arterioles compared with C (p < 0.05). Liver expression profiles of peroxisome proliferator-activated receptor (PPAR) a, PPARy, and PPAR-regulated genes revealed encouraging CB-induced effects. Discussion: These results suggest that (+)-Z-BDDA may have applications in treating obesity and complications associated with the metabolic syndrome.

Revue / Journal Title

Obesity research   ISSN 1071-7323   CODEN OBREFR 

Source / Source

2005, vol. 13, n^o11, pp. 1915-1924 [10 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

North American Association for the Study of Obesity, Silver Spring, MD, ETATS-UNIS  (1993-2005) (Revue)

Mots-clés d'auteur / Author Keywords

(+)-Z-bisdehydrodoisynolic acid ; insulin resistance ; selective estrogen receptor modulators ; peroxisome proliferator-activated receptor ; Zucker Diabetic Fatty rat ;

Localisation / Location

INIST-CNRS, Cote INIST : 26394, 35400013457776.0090